 Aurinia Pharmaceuticals Inc NASDAQ: AUPH has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis voclosporin in lupus nephritis. Data will be presented at the upcoming European Alliance of Associations for Rheumatology EULAR 2021 Congress in June. 